» Articles » PMID: 39253899

Factors Associated with Stellate Ganglion Block Success in Recurrent Ventricular Arrhythmias

Overview
Journal ESC Heart Fail
Date 2024 Sep 10
PMID 39253899
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: One treatment option for refractory ventricular arrythmias is stellate ganglion block (SGB). We examined differences in SGB success by patient and arrhythmia characteristics and predictors of successful SGB.

Methods And Results: This was a multicenter analysis of patients treated for refractory ventricular arrythmias in the Czech Republic and the United States. The primary outcome was absence of ventricular arrythmias at 24 h post SGB. SGB effectiveness was examined according to aetiology of cardiomyopathy, arrhythmia type, laterality of SGB, presence of inotropes, and presence of mechanical circulatory support. Binary logistic regression was used to examine variables associated with the primary outcome. In total there were 117 patients with refractory ventricular arrythmias treated with SGB. Overall, the mean age was 63.5 ± 11.0 years, majority of patients were male (94.0%), White (87.2%), and had an implantable cardioverter defibrillator in situ (70.1%). There were no differences in efficacy of SGB based on aetiology of cardiomyopathy (P = 0.623), arrhythmia type (0.852), laterality of block (P = 0.131), and presence of inotropes (P = 0.083). Multivariable analysis demonstrated that increased age was associated with decreased odds of SGB success (odds ratio: 0.96, confidence interval: 0.92-0.99, P = 0.039) whereas increased left ventricular ejection fraction trended towards increased odds of SGB success (odds ratio: 1.05, confidence interval: 0.995-1.11, P = 0.077).

Conclusions: In this multicentre experience, SGB was similarly effective despite the aetiology of cardiomyopathy, type of arrhythmia, laterality, and inotropic or mechanical support. SGB was less effective for the suppression of ventricular arrythmias at 24 h for the elderly.

Citing Articles

Factors associated with stellate ganglion block success in recurrent ventricular arrhythmias.

Chouairi F, Fudim M, Benak A, Piccini J, Toman J, Kautzner J ESC Heart Fail. 2024; 12(1):110-117.

PMID: 39253899 PMC: 11769651. DOI: 10.1002/ehf2.15072.

References
1.
Fudim M, Boortz-Marx R, Patel C, Sun A, Piccini J . Autonomic Modulation for the Treatment of Ventricular Arrhythmias: Therapeutic Use of Percutaneous Stellate Ganglion Blocks. J Cardiovasc Electrophysiol. 2016; 28(4):446-449. DOI: 10.1111/jce.13152. View

2.
Bradfield J, Ajijola O, Vaseghi M, Shivkumar K . Mechanisms and management of refractory ventricular arrhythmias in the age of autonomic modulation. Heart Rhythm. 2018; 15(8):1252-1260. DOI: 10.1016/j.hrthm.2018.02.015. View

3.
Burzotta F, Trani C, Doshi S, Townend J, van Geuns R, Hunziker P . Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user group. Int J Cardiol. 2015; 201:684-91. DOI: 10.1016/j.ijcard.2015.07.065. View

4.
Harding J, Piacentino 3rd V, Rothman S, Chambers S, Jessup M, Margulies K . Prolonged repolarization after ventricular assist device support is associated with arrhythmias in humans with congestive heart failure. J Card Fail. 2005; 11(3):227-32. DOI: 10.1016/j.cardfail.2004.08.158. View

5.
Fudim M, Qadri Y, Waldron N, Boortz-Marx R, Ganesh A, Patel C . Stellate Ganglion Blockade for the Treatment of Refractory Ventricular Arrhythmias. JACC Clin Electrophysiol. 2020; 6(5):562-571. DOI: 10.1016/j.jacep.2019.12.017. View